Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Yongkun Wei

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8998-5333; OpenAlex author ID A5109411868. Sources: OpenAlex.

Their work

Papers
7 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
37
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 2 papers · 2025: 1 paper · 2026: 2 papers

Papers 7

  1. Syndecan-1-targeted therapeutic antibody impairs macropinocytosis and elicits antitumor immunity in pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2026.102613↗
  2. All-trans retinoic acid destabilizes ADAR1 protein through retinoylation-mediated USP7 dissociation and improves immunotherapy in pancreatic cancer. First author DOI 10.1038/s41467-026-72271-5↗
  3. KRAS Inhibition Activates an Actionable CD24 "Do Not Eat Me" Signal in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-2024↗
  4. Targeting a chemo-induced adaptive signaling circuit confers therapeutic vulnerabilities in pancreatic cancer. Co-author DOI 10.1038/s41421-024-00720-w↗
  5. All-trans retinoic acid-mediated ADAR1 degradation synergizes with PD-1 blockade to suppress pancreatic cancer Co-author DOI 10.1101/2024.10.20.619300↗
  6. Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2018.02.012↗
  7. Oncogenic Functions of Gli1 in Pancreatic Adenocarcinoma Are Supported by Its PRMT1-Mediated Methylation. Co-author DOI 10.1158/0008-5472.can-16-0715↗

Closest collaborators

The 25 strongest of 37 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Haoqiang Ying · 6 shared papers, 2018–2026 · strength 0.96
  2. Huamin Wang · 5 shared papers, 2016–2026 · strength 0.62
  3. Mien‐Chie Hung · 5 shared papers, 2016–2026 · strength 0.61
  4. Wantong Yao · 3 shared papers, 2025–2026 · strength 0.60
  5. Anirban Maitra · 4 shared papers, 2018–2026 · strength 0.57
  6. Ching-Fei Li · 3 shared papers, 2024–2026 · strength 0.54
  7. Paul J. Chiao · 3 shared papers, 2024–2026 · strength 0.51
  8. Dihua Yu · 3 shared papers, 2024–2026 · strength 0.51
  9. Ying‐Nai Wang · 3 shared papers, 2018–2026 · strength 0.42
  10. Timothy Paul Heffernan · 2 shared papers, 2025–2026 · strength 0.39
  11. Jun Yao · 3 shared papers, 2018–2025 · strength 0.37
  12. Jianhua Ling · 2 shared papers, 2024–2026 · strength 0.37
  13. Jie Fu · 2 shared papers, 2024–2026 · strength 0.37
  14. Li‐Yuan Bai · 2 shared papers, 2024–2026 · strength 0.37
  15. Ronald Anthony Depinho · 2 shared papers, 2024–2025 · strength 0.32
  16. Ignacio Ivan Wistuba Oyarzun · 1 shared paper, 2026 · strength 0.22
  17. Zecheng Yang · 1 shared paper, 2026 · strength 0.22
  18. Giulio Francesco Draetta · 1 shared paper, 2026 · strength 0.22
  19. Cheng‐Wei Chou · 1 shared paper, 2026 · strength 0.21
  20. Rosa F. Hwang · 2 shared papers, 2016–2024 · strength 0.19
  21. Andrea Viale · 1 shared paper, 2025 · strength 0.17
  22. Dan Zhao · 1 shared paper, 2025 · strength 0.17
  23. Abdelrahman M.G. Yousef · 1 shared paper, 2025 · strength 0.17
  24. Hong Zhao · 1 shared paper, 2025 · strength 0.17
  25. Yohei Saito · 1 shared paper, 2024 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.